The impact of drug-induced QT interval prolongation on drug discovery and development

Nature Reviews Drug Discovery

Volumn 2, Issue 6, 2003, Pages 439-447

  Fermini, Bernard ^a   Fossa, Anthony A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJMALINE; ALMOKALANT; AMIODARONE; AMITRIPTYLINE; AZIMILIDE; BRETYLIUM; CLARITHROMYCIN; CLOFILIUM; DISOPYRAMIDE; DOFETILIDE; ERYTHROMYCIN; FEXOFENADINE; FLECAINIDE; IBUTILIDE; ISRADIPINE; ITRACONAZOLE; KETANSERIN; KETOCONAZOLE; LIDOFLAZINE; NICARDIPINE; PRENYLAMINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SEMATILIDE; SOTALOL; TERFENADINE; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL; CARDIOVASCULAR AGENT;

ARRHYTHMOGENESIS; CARDIOTOXICITY; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUDDEN DEATH; TORSADE DES POINTES; ANIMAL; CHEMICALLY INDUCED DISORDER; ECONOMICS; LEGAL ASPECT; METHODOLOGY; PATHOPHYSIOLOGY; PHARMACEUTICS;

ANIMALS; CARDIOVASCULAR AGENTS; HUMANS; LONG QT SYNDROME; TECHNOLOGY, PHARMACEUTICAL;

EID: 0038471102     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1108     Document Type: Review

References (39)

1. Roden, D. M. & Balser, J. R. A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology. Cardiovasc. Res. 44, 242-246 (1999).
2. Antzelevitch, C. & Shimizu, W. Cellular mechanisms underlying the long OF syndrome. Curr. Opin. Cardiol. 17, 43-61 (2002).
3. Woosley, R. L. Drugs that prolong the QT interval and/or induce torsades de pointes [online], (cited 17 December 2002), http://www.qtdrugs.org/medical-pros/drug-lists/drug-lists.Htm (2002).
4. Dmitrienko, A. A. et al. Electrocardiogram reference ranges for Lilly clinical trials. Eli Lilly and Company, March 2002.
5. Linquist, M. & Edwards, R. Risks of non-sedating antihistamines. Lancet 349, 1322 (1997).
6. Bauman, J. L. et al. Torsade de Pointes due to quinidine: observations in 31 patients. Am. Heart J. 107, 425-430 (1984).
7. Bednar, M. M., Harrigan, E. P., Anziano, R. J., Camm, A. J. & Ruskin, J. N. The QT Interval. Prog. Cardiovasc. Dis. 43, 1-45 (2001).
8. DeCicco, M. et al. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion. Crit. Care Med. 27, 332-339 (1999).
9. Winters, S. L., Scheitzer, P., Kupersmith, J. & Gomes, J. A. Verapamil-induced polymorphous ventricular tachycardia. J. Am. Coll. Cardiol. 6, 257-259 (1985).
10. Haverkamp, W. et al. Torsade de pointes induced by d, I-sotalol. Circulation 88, S2131 (1993).
11. Woosley, R. L., Chen, Y., Freiman, J. P. & Gillis, R. A. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269, 1532-1536 (1993).
12. Shah, R. R. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labeling of a new chemical entity. Fundam. Clin. Pharmacol. 16, 147-156 (2002).
13. Davies, A. J., Harinda, V., McEwan, A. & Ghose, R. R. Cardiotoxic effect with convulsions in terfenadine overdose. Br. Med. J. 298, 325 (1989).
14. Monahan, B. P. et al. Torsades de Pointes occurring in association with terfenadine use. JAMA 264, 2788-2790 (1990).
15. Kemp, J. P. Antihistamines - is there anything safe to prescribe? Ann. Allergy 69, 276-280 (1992).
16. Roy, M. L., Dumaine, R. & Brown, A. M. HERG, a primary human ventricular target of the non-sedating antihistamine terfenadine. Circulation 94, 817-823 (1996).
17. Zipes, D. P. Unwitting exposure to risk, Cardiol. Rev. 1, 1-3 (1993).
18. Committee for Proprietary Medicinal Product (CPMP): Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products, London, England. Human Medicines Evaluation Unit (1997).
19. Assessment of the QT Prolongation Potential of Non-Antiarrhythmic Drugs, Health Canada, Therapeutic Products Directorate (March 15 2001).
20. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Preliminary concept paper FDA (January 28 2003).
21. Guideline on safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. ICH S7B. The European Agency for the Evaluation of Medicinal Products CPMP/ICH/423/02 (February 2003).
22. Mitcheson, J. S., Chen, J., Lin, M., Culberson, C. & Sanguinetti, M. C. A structural basis for drug-induced long QT syndrome. Proc. Natl Acad. Sci. USA 97, 12329-12333 (2000).
23. Kiss, L. et al. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev. Technol. 1, 127-135 (2003).
24. + channel. Circ. Res. 72, 707-714 (1993).
25. + channel? Eur. J. Pharmacol. 412, 203-212 (2001).
26. González, J. E., Oades, K., Leychkis, Y., Harootunian, A. & Negulescu, P. A. Cell-based assays and instrumentation for screening ion-channel targets. Drug Discov. Today 4, 431-439 (1999).
27. Gintant, G. A., Limberis, J. T., McDermott, J. S., Wegner, C. D. & Cox, B. F. The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol. 37, 607-618 (2001).
28. Patmore, L., Fraser, S., Mair, D. & Templeton, A. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur. J. Pharmacol. 406, 449-452 (2000).
29. Cavero, I., Mestre, M., Guillon, J. M. & Crumb, W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin. Pharmacother. 1, 947-973 (2000).
30. Champeroux, P. et al. The pre-clinical assessment of the risk for QT interval prolongation. Therapie 55, 101-109 (2000).
31. Redfern, W. S., et al. Relationships between pre-clinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45 (2003).
32. Food and Drug Administration. Center for Drug Evaluation and Research. Proposed standard for exchange of electrocardiographic data. Bethesda, Maryland (November 19 2001).
33. Shah, R. R. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fund. Clin. Pharmacol. 16, 147-156 (2002).
34. Witchel, H. J., Pabbathi, V. K., Hofmann, G., Paul, A. A. & Hancock, J. C. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett. 512, 59-66 (2002).
35. Ellison, J. M., Milofsky, J. E. & Ely, E. Fluoxetine-induced bradycardia and syncope in two patients. J. Clin. Psychiatry 51, 385-386 (1990).
36. Raviña, T., Suarez, M. L. R. & Mendez-Castrillón, J. Fluoxetine-induced QTU interval prolongation, T wave alternans and syncope. Int. J. Cardiol. 65, 311-313 (1998).
37. Varriale, P. Fluoxetine (Prozac) as a cause of QT prolongation. Arch. Inter. Med. 161, 612 (2001).
38. Spier, S. A. & Frontera, M. A. Unexpected deaths in depressed medical inpatients treated with fluoxetine. J. Clin. Psychiatry 52, 377-382 (1991).
39. Roden, D. M., Balser, J. R., George, A. L. & Anderson, M. E. Cardiac ion channels. Annu. Rev. Physiol. 64, 431-475 (2002).